Advertisement
"The ColonSentry test is a breakthrough risk-assessment tool that provides a more accurate and reliable basis for recommending colonoscopies than demographic benchmarks or the less sophisticated occult blood stool test. We believe that these traditional guidelines result in overlooked risk for the patient," said Dr. Elaine Chin, Chief Medical Officer and co-founder of Scienta Health. "Alternatively, this patient-friendly blood test will provide diagnostic information to allow physicians to make better decisions regarding next steps in the colorectal cancer screening process. Ultimately, the ColonSentry(TM) test may help identify the presence of this cancer in patients at a curable stage providing individualized preventative health care for our patients, which is fundamental to Scienta's core commitment to our patients."
Advertisement
"Scienta is a leader in individualized preventive medicine and as the first executive health clinic to offer our ColonSentry test, their patients will now have access to this unique and powerful risk-assessment tool among their robust suite of health care services," said Dr. Heiner Dreismann, interim CEO and Lead Director of GeneNews. "Our partnership with Scienta is a good example of one component in our commercialization strategy for ColonSentry. In the coming months, we expect to rollout our test in additional regions in Canada and target private health insurers to include our test under their healthcare offerings." For more information on the ColonSentry test, please visit www.colonsentry.com.
Scienta Health specializes in individualized preventive medicine. The clinic is renowned for its expertise in applying the latest science to health screening and disease prevention. Scienta is the first executive health clinic to offer ColonSentry to its clients and the test will be an optional component in their comprehensive annual health assessments. For additional information please visit www.scientahealth.com.
About GeneNews
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
